This test detects antibodies that target citrullinated peptides, which form when certain proteins undergo a natural chemical change (citrullination).
Diagnostic Value: Anti-CCP antibodies are among the most specific markers for Rheumatoid Arthritis (RA) and are included in the formal diagnostic criteria for the disease.
Clinical Significance: The CCP3.1 assay measures both IgG and IgA antibodies, providing a highly sensitive and specific tool for early detection of RA — sometimes even before symptoms appear.
Symptom Correlation: Patients with Anti-CCP antibodies may experience joint pain, stiffness (especially in the morning), and swelling that typically affects the small joints of the hands and feet.
The CCP3.1 test helps identify patients at risk for developing RA and guides early, targeted treatment to prevent irreversible joint damage.